Our study not only emphasizes the regulatory mechanism of SETD2 in CML, but also provides promising therapeutic strategies for overcoming the imatinib resistance in patients with CML. The gene discussed is SETD2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.